Latest News 2021: All information related to the latest news alerts in the SFVSl News 2021 portal is now being made available in English language, so that you will get the first news updates of all business and car-bikes in India.
All news related to country, world, entertainment, sports, business, and politics. Find all the latest English news, breaking news at Shortfilmvideostatus.com.
यह खबर नवभारत टाइम्स की ओर से आई है
[ad_1]
Highlights:
- This trial will be done on volunteers involved in phase two
- In a trial involving 200 people out of 400
- Trial to see differences in antibody levels
Trial of booster dose of covaxin has started in AIIMS Delhi. Kovacsin manufacturer Bharat Biotech has started a booster dose trial from Monday. The booster dose trials include those who have completed six months for the second dose during Phase II trials, ie those who were vaccinated between September and October last year. Bharat Biotech received approval from an expert panel of the Drug Controller General of India (DCGI) in April to conduct a clinical trial for the third dose of covaxine, the booster dose.
Pfizer Vaccine India: Research reveals, delay in second dose of Pfizer vaccine increases immunity in the elderly
Let me tell you that earlier American vaccine maker Pfizer and Moderna announced that those who have given both doses of Pfizer-BioNotech or Moderna Kovid-19 Vaccine will need booster shot this year and after that every A yearly shot may also be needed.
Bharat Biotech Covaxin WHO latest news: Bharat Biotech handed over 90% of the documents to WHO for listing covaxin
According to the information received from AIIMS, the purpose of this trial is to know whether there is any difference in the antibody level after the booster dose. If there is a big difference in making antibodies from the booster dose, then it will be considered, but if there is no specific benefit, it may be that the booster is not needed at all. But now it will depend on the trial. For this, AIIMS is taking about 200 of the 400 people involved in the second phase. This 200 will be divided into two groups and one group will be given the booster dose of vaccine and the other group will be given placebo. After that a computational study of both the groups will be done, on the basis of which it can be decided whether the booster dose is beneficial or not.
Trial of booster dose of covaxine begins
[ad_2]
Social Plugin